0.20
+2.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About VolitionRX
From its filings with the US Securities and Exchange Commission
VolitionRX is based in Henderson, Nevada and is incorporated in Delaware. Its shares trade on NYSE under the ticker VNRX. The SEC classifies its business as in vitro & in vivo diagnostic substances. In the fiscal year to 31 December 2025, it reported revenue of $1.7m and a net loss of $23.4m. At that date it held total assets of $6.9m and shareholders' equity of −$34.2m.
Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests.
Volition is a multi-national epigenetics company. It has patented technologies that use chromosomal structures, such as nucleosomes, and transcription factors as biomarkers in cancer and other diseases. The tests in the Company’s product portfolio detect certain characteristic changes that occur from the earliest stages of disease, enabling early detection and offering a better way to monitor disease progression and a patient’s response to treatment.
The tests offered by Volition and its subsidiaries are designed to detect and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life.
Nu.Q® Vet - cost-effective, easy-to-use blood tests for dogs and other companion animals. The Nu.Q® Vet Cancer Test is commercially available as a cancer screening test in dogs.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 6 Feb 2015
- Employees
- 50
- Website
- volitionrx.com ↗
- Head office
- 1489 WEST WARM SPRINGS ROAD, HENDERSON, NV, 89014
- Incorporated in
- DE
- Classification
- In Vitro & In Vivo Diagnostic Substances
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Timothy StillNon-Executive Chairman of the Board$82,793
- Mr. Cameron ReynoldsPresident, Chief Executive Officer, Director, since 2011$614,814
- Mr. Terig HughesChief Financial Officer, Treasurer$513,225
- Dr. Salvatore ButeraChief Executive Officer of Volition Vet, since 2020$428,419
- Dr. Jasmine KwayChief Executive Officer of Singapore Volition
- Dr. Gaetan MichelChief Operating Officer$521,041
- Ms. Louise BatchelorGroup Chief Marketing and Communications Officer
- Dr. Jacob MicallefChief Scientific Officer$657,886
- Mr. Nicholas PlummerGroup General Counsel
- Mr. Gael ForterreChief Commercial Officer
- Dr. Andrew RetterChief Medical Officer
- Mr. Rodney RootsaertCorporate Secretary$262,724
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 55
- Social
- 61
- Governance
- 40
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- VolitionRX Ltd has a strong intellectual property portfolio, which provides a competitive advantage in the field of diagnostics and cancer detection. The company's innovative technology and patented products set it apart from competitors.
- VolitionRX Ltd has successfully built strategic partnerships and collaborations with leading healthcare organizations and research institutions. These partnerships provide access to valuable resources, expertise, and networks, enhancing the company's capabilities and market reach.
- The company has a dedicated and experienced management team with a track record of driving growth and innovation. Their expertise in the healthcare industry and business acumen contribute to the development and execution of successful business strategies.
Weaknesses
- VolitionRX Ltd faces significant competition from established players in the diagnostics and cancer detection market. The company's relatively smaller size and limited resources may pose challenges in terms of marketing and market penetration.
- The company's products are still in the development and clinical trial stages, which can lead to uncertainties and delays. VolitionRX Ltd needs to manage these risks effectively to ensure timely product commercialization and revenue generation.
- VolitionRX Ltd may also face regulatory hurdles and compliance requirements, especially when seeking approvals for its diagnostic products in different countries. This can impact the speed of market entry and limit revenue potential.
Opportunities
- The growing demand for non-invasive and accurate cancer detection methods presents a significant opportunity for VolitionRX Ltd. The company's innovative technology has the potential to revolutionize the diagnostics industry and capture a substantial market share.
- VolitionRX Ltd can explore potential partnerships and collaborations with pharmaceutical companies for co-development and commercialization of companion diagnostics. This would not only enhance the company's product offerings but also increase market access and revenue potential.
- The increasing adoption of personalized medicine and targeted therapies creates a favorable market environment for VolitionRX Ltd. By aligning its products with these trends, the company can position itself as a key player in the evolving healthcare landscape.
Threats
- VolitionRX Ltd operates in a highly regulated and competitive market, which poses threats to its growth and profitability. The presence of established players with established brands, distribution networks, and customer loyalty can make it challenging to gain market share.
- Economic and geopolitical factors can also impact VolitionRX Ltd's business operations by affecting healthcare spending, market dynamics, and investor sentiment. Volatility in financial markets and economic downturns can disrupt funding and hinder the company's growth plans.
- Rapid advancements in technology and emerging competitors pose a threat to VolitionRX Ltd's market position and product relevance. The company needs to stay at the forefront of innovation and continuously adapt its products to address changing customer needs and preferences.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.